Biome Australia Limited (BIO.AX)
AUD 0.57
(4.63%)
AUD 0.57
(4.63%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -1.56 Million AUD | -40.98% |
| 2023 | -1.11 Million AUD | 77.81% |
| 2022 | -5.02 Million AUD | 44.89% |
| 2021 | -9.12 Million AUD | -29489.02% |
| 2020 | 31.03 Thousand AUD | 107.08% |
| 2019 | -438.01 Thousand AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -676.74 Thousand AUD | 86.54% |
| 2024 Q4 | -1.56 Million AUD | 0.0% |
| 2024 FY | -1.56 Million AUD | -40.14% |
| 2024 Q2 | -573.04 Thousand AUD | 15.32% |
| 2023 Q2 | -3.31 Million AUD | 2.8% |
| 2023 FY | -1.11 Million AUD | 77.81% |
| 2023 Q3 | -1.21 Million AUD | 63.33% |
| 2023 Q1 | -3.4 Million AUD | 32.93% |
| 2023 Q4 | -5.02 Million AUD | -313.78% |
| 2022 Q2 | -7.3 Million AUD | 0.2% |
| 2022 FY | -5.02 Million AUD | 44.89% |
| 2022 Q4 | -5.08 Million AUD | 0.72% |
| 2022 Q3 | -5.11 Million AUD | 29.95% |
| 2022 Q1 | -7.32 Million AUD | -1221.11% |
| 2021 Q4 | -554.19 Thousand AUD | -4.65% |
| 2021 Q3 | -529.56 Thousand AUD | 0.0% |
| 2021 Q1 | 448.86 Thousand AUD | 0.0% |
| 2021 FY | -9.12 Million AUD | -29489.02% |
| 2020 FY | 31.03 Thousand AUD | 107.08% |
| 2019 FY | -438.01 Thousand AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | -18.89 Million AUD | 91.731% |
| Anatara Lifesciences Ltd | -982.1 Thousand AUD | -59.128% |
| Zelira Therapeutics Limited | 5.06 Million AUD | 130.841% |
| Patrys Limited | -2.24 Million AUD | 30.252% |
| Orthocell Limited | -19.92 Million AUD | 92.156% |
| Imugene Limited | -91.56 Million AUD | 98.293% |
| Noxopharm Limited | -2.31 Million AUD | 32.636% |
| PYC Therapeutics Limited | -65.76 Million AUD | 97.624% |
| Chimeric Therapeutics Limited | -3.05 Million AUD | 48.811% |
| Prescient Therapeutics Limited | -10.16 Million AUD | 84.622% |
| Proteomics International Laboratories Limited | -6.32 Million AUD | 75.287% |
| Cynata Therapeutics Limited | -6.2 Million AUD | 74.815% |
| CSL Limited | 15.76 Billion AUD | 100.01% |
| Arovella Therapeutics Limited | -12.71 Million AUD | 87.708% |
| Bio-Gene Technology Limited | -709.55 Thousand AUD | -120.251% |
| Clinuvel Pharmaceuticals Limited | -182.98 Million AUD | 99.146% |
| Starpharma Holdings Limited | -19.83 Million AUD | 92.12% |
| Nanollose Limited | -96.22 Thousand AUD | -1524.117% |
| Memphasys Limited | 4.13 Million AUD | 137.791% |
| Invex Therapeutics Ltd | -6.02 Million AUD | 74.062% |
| NeuroScientific Biopharmaceuticals Limited | -4.95 Million AUD | 68.455% |
| Amplia Therapeutics Limited | -1.82 Million AUD | 14.301% |
| Botanix Pharmaceuticals Limited | -79.3 Million AUD | 98.029% |
| Island Pharmaceuticals Limited | -1.23 Million AUD | -26.195% |
| Race Oncology Limited | -17.18 Million AUD | 90.908% |
| Nyrada Inc. | -4.76 Million AUD | 67.232% |
| Telix Pharmaceuticals Limited | -105.79 Million AUD | 98.523% |
| Dimerix Limited | -21.99 Million AUD | 92.894% |
| PharmAust Limited | -9.71 Million AUD | 83.912% |
| Immutep Limited | -122.18 Million AUD | 98.721% |
| Clarity Pharmaceuticals Ltd | -136.5 Million AUD | 98.855% |
| Alterity Therapeutics Limited | -12.47 Million AUD | 87.477% |
| BTC Health Limited | -2.02 Million AUD | 22.716% |
| Acrux Limited | -1.45 Million AUD | -7.188% |
| Neuren Pharmaceuticals Limited | -17.09 Million AUD | 90.858% |
| Biotron Limited | -386.06 Thousand AUD | -304.801% |
| Tissue Repair Ltd | -16.44 Million AUD | 90.494% |
| AdAlta Limited | -845.17 Thousand AUD | -84.91% |
| Radiopharm Theranostics Limited | -18.57 Million AUD | 91.587% |
| Hexima Limited | -2.22 Million AUD | 29.8% |
| AnteoTech Limited | -5 Million AUD | 68.753% |
| Paradigm Biopharmaceuticals Limited | -17.58 Million AUD | 91.111% |
| Recce Pharmaceuticals Ltd | -3.39 Million AUD | 53.983% |
| Avecho Biotechnology Limited | -5.32 Million AUD | 70.675% |
| Actinogen Medical Limited | -9.13 Million AUD | 82.886% |
| Immuron Limited | -11.48 Million AUD | 86.391% |
| Argenica Therapeutics Limited | -15.91 Million AUD | 90.179% |